メデトミジン

Danger

H300: Fatal if swallowed [Danger Acute toxicity, oral]

P260, P261, P264, P270, P271, P273, P284, P301+P316, P304+P340, P308+P316, P316, P319, P320, P321, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Danger

H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]

P260, P264, P270, P271, P273, P284, P301+P316, P304+P340, P316, P320, P321, P330, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Acute Tox. 2 (100%)

Acute toxicity (inhalation) - category 2

Acute Tox. 2

A 2026 "Emergence of Medetomidine in the Illicit Drug Supply: Implications for Emergency Care and Withdrawal Management" publication notes that Medetomidine is a racemic mixture of levomedetomidine and the more active dexmedetomidine enantiomers. It can produce prolonged sedation, bradycardia, and biphasic blood pressure effects. Emergency care is complicated since the toxicity persists after naloxone administration. Withdrawal is rapidly progressive, severe, and often resistant to traditional therapies, and the symptoms can begin within four-to-six hours after the last use. The withdrawal symptoms include anxiety, tremor, vomiting, hypertension, tachycardia, and delirium whilethe laboratory findings may include lactic acidosis, hypokalemia, and QTc prolongation.

Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.

A subclass of analgesic agents that typically do not bind to OPIOID RECEPTORS and are not addictive. Many non-narcotic analgesics are offered as NONPRESCRIPTION DRUGS.

Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.

A 2026 "Emergence of Medetomidine in the Illicit Drug Supply: Implications for Emergency Care and Withdrawal Management" publication notes that Medetomidine is readily available after intravenous injection and that it can be absorbed through the nasal and buccal mucosa. Extensive first-pass effects limit bioavailability after ingestion.